H H Lundbeck A-S
H
Ouvert
41.88 1.7
Résumé
Variation du prix de l'action
24h
Min
41.04
Max
42.32
Revenu | 1.7B 1.7B |
|---|---|
Ventes | 1.2B 7B |
P/E Moyenne du Secteur | 10.676 49.701 |
BPA | 0.94 |
Rendement du dividende | 2.78 |
Marge bénéficiaire | 23.601 |
Employés | 5,000 |
EBITDA | 598M 2.4B |
Rendement du dividende Moyenne du Secteur | 2.78% 2.39% |
|---|
Capitalisation Boursière | -2.1B 40B |
|---|---|
Ouverture précédente | 40.18 |
Clôture précédente | 41.88 |
H Lundbeck A-S Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
H Lundbeck A-S prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos H Lundbeck A-S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
